Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin
- PMID: 1834010
- PMCID: PMC284292
- DOI: 10.1128/AAC.35.6.1089
Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin
Abstract
The effect of protein binding on the activity of teicoplanin against Staphylococcus aureus was evaluated. Bactericidal rates of teicoplanin in cation-supplemented Mueller-Hinton broth (SMHB) and in a 1:1 mixture of pooled human serum and cation-supplemented Mueller-Hinton broth (PHS-SMHB) were compared with those of vancomycin. Eight concentrations of each drug ranging from 15 to 150 micrograms/ml were studied in two series which correspond to the concentrations in serum achieved with low- (6 mg/kg of body weight once daily) and high-dose (30 mg/kg once daily) teicoplanin. Overall, the bactericidal rate of teicoplanin was lower than that of vancomycin. In the presence of serum, the bactericidal rate of teicoplanin in PHS-SMHB was lower than that in SMHB, often resulting in only one log10 drop in CFU over a 24-h period. There was no statistical difference in the bactericidal rates of high- and low-concentration teicoplanin in either medium. Additionally, concentration-dependent killing in SMHB was not evident with either agent. The bactericidal rates of teicoplanin and vancomycin in a 1:1 mixture of serum ultrafiltrate and SMHB at 60 micrograms/ml were also studied. It was noted that the bactericidal rate of neither agent was affected by the presence of serum ultrafiltrate. This finding is consistent with teicoplanin's high degree of protein binding (reported to be greater than 90% in undiluted serum) and further substantiates the hypothesis that only the free drug is active against microorganisms. These data support protein binding as being a factor in teicoplanin activity against S. aureus.
Similar articles
-
Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus.Pharmacotherapy. 1994 Jan-Feb;14(1):35-9. doi: 10.1002/j.1875-9114.1994.tb02786.x. Pharmacotherapy. 1994. PMID: 8159599
-
Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies.Diagn Microbiol Infect Dis. 1990 May-Jun;13(3):245-52. doi: 10.1016/0732-8893(90)90067-6. Diagn Microbiol Infect Dis. 1990. PMID: 2166634
-
Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin.J Antimicrob Chemother. 1986 Oct;18(4):513-20. doi: 10.1093/jac/18.4.513. J Antimicrob Chemother. 1986. PMID: 2945811 Clinical Trial.
-
[A comparative microbiological and pharmacokinetic activity of vancomycin and teicoplanin].Pathol Biol (Paris). 1992 Oct;40(8):831-44. Pathol Biol (Paris). 1992. PMID: 1484744 Review. French.
-
Teicoplanin in peritoneal dialysis: efficacy, safety, and pharmacological considerations.Ann Med Surg (Lond). 2024 May 15;86(8):4575-4578. doi: 10.1097/MS9.0000000000002171. eCollection 2024 Aug. Ann Med Surg (Lond). 2024. PMID: 39118702 Free PMC article. Review.
Cited by
-
Interspecies variability in protein binding of antibiotics basis for translational PK/PD studies-a case study using cefazolin.Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0164723. doi: 10.1128/aac.01647-23. Epub 2024 Feb 20. Antimicrob Agents Chemother. 2024. PMID: 38376186 Free PMC article.
-
Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia.Clin Drug Investig. 1996 Aug;12(2):80-7. doi: 10.2165/00044011-199612020-00003. Clin Drug Investig. 1996. PMID: 24610668
-
Effect of ertapenem protein binding on killing of bacteria.Antimicrob Agents Chemother. 2004 Sep;48(9):3419-24. doi: 10.1128/AAC.48.9.3419-3424.2004. Antimicrob Agents Chemother. 2004. PMID: 15328106 Free PMC article.
-
Usefulness of teicoplanin for preventing methicillin-resistant Staphylococcus aureus infections in orthopedic surgery.Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):35-8. doi: 10.1007/s10096-005-0073-z. Eur J Clin Microbiol Infect Dis. 2006. PMID: 16424973
-
Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.Clin Pharmacokinet. 2018 Jul;57(7):797-816. doi: 10.1007/s40262-017-0623-4. Clin Pharmacokinet. 2018. PMID: 29332251 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical